Urinary incontinence (UI) is a very common condition that can affect patients of all ages and the commonest cause is an overactive bladder (OAB). Most patients with OAB were treated with pharmacotherapy and major surgery. Over 25 years ago, Dasgupta, Fowler et al. studied the presence and role of C fibres in the human bladder which are highly sensitive to capsaicin, the active ingredient of chillies. When capsaicin was instilled into patients' bladders as a synthetic solution, it was found to be highly effective in some patients. Capsaicin was later replaced by Resiniferatoxin. Both toxins desensitised C-fibres through the capsaicin receptor, TRPV1, without any lasting damage to the bladder itself. The discovery of botulinum toxin and its use in the treatment of OAB represents a major breakthrough, in the treatment of OAB. Another key innovation was the development of technique to administer the drug under local anaesthesia which allowed numerous patients to benefit from treatment who would otherwise have been precluded because of the need for injection under general anaesthetic. After extensive trials over many years Botox (OnabotulinumtoxinA) is now licensed for use in OAB. Compared to other treatments for overactive bladder, OnabotulinumtoxinA is more cost-effective and less invasive. It is thought to have changed the quality of life of an estimated 5 million patients worldwide.
The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland. 2022 Oct 26 [Epub]
Nawal Khan, Muhammad Shamim Khan, Sachin Malde, Arun Sahai, Prokar Dasgupta
King's College London, Guy's and St. Thomas' Hospitals, King's Health Partners, London, UK; Department of Urology, The London Clinic, W1G 6BW, UK. Electronic address: ., King's College London, Guy's and St. Thomas' Hospitals, King's Health Partners, London, UK., King's College London, Guy's and St. Thomas' Hospitals, King's Health Partners, London, UK; Department of Urology, The London Clinic, W1G 6BW, UK.